Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ELIZABETH SHPALL and ROBERT C BAST JR.
Connection Strength

0.302
  1. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood. 1994 Jun 01; 83(11):3132-7.
    View in: PubMed
    Score: 0.030
  2. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun; 11(6):1132-43.
    View in: PubMed
    Score: 0.028
  3. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer. 1991 Nov 11; 49(5):704-10.
    View in: PubMed
    Score: 0.025
  4. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. Cancer. 1991 Sep 15; 68(6):1272-8.
    View in: PubMed
    Score: 0.025
  5. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant. 1991 Feb; 7(2):145-51.
    View in: PubMed
    Score: 0.024
  6. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol. 1991 Jan; 9(1):85-93.
    View in: PubMed
    Score: 0.024
  7. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol. 1990 Sep; 38(3):386-91.
    View in: PubMed
    Score: 0.023
  8. Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am J Clin Pathol. 1990 Jul; 94(1):8-13.
    View in: PubMed
    Score: 0.023
  9. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. Prog Clin Biol Res. 1990; 333:321-35; discussion 336.
    View in: PubMed
    Score: 0.022
  10. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res. 1989 Aug 15; 49(16):4659-64.
    View in: PubMed
    Score: 0.022
  11. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988 Apr 07; 318(14):869-76.
    View in: PubMed
    Score: 0.020
  12. The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. Cancer. 1990 Aug 01; 66(3):431-6.
    View in: PubMed
    Score: 0.012
  13. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat. 1996; 41(1):1-13.
    View in: PubMed
    Score: 0.008
  14. Detection of minimal residual breast cancer in bone marrow. Prog Clin Biol Res. 1992; 377:637-42.
    View in: PubMed
    Score: 0.006
  15. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol. 1989; 23(6):377-83.
    View in: PubMed
    Score: 0.005
  16. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988 Sep; 6(9):1368-76.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.